Mike,
I think ABI is going to be stuck in neutral for a while. Sequencers not selling well, and customers using less reagents as they learn to use their sequencers more efficiently. Of the two trickle companies you mention, I would go with Agilent, as I think it could turn around faster, once the capex spigot in the sector turns on. BDAL, WAT, QGENF, EBIO, IVGN, (perhaps APO, which had a good quarter, but I don't follow it) all look more attractive to me here, FWIW. The theory is that mass specs and reagents are still selling. Disclosure, I own both BDAL and QGENF. Recently added to the latter.
Does the Thread of Life Portfolio short anything? I'd be tempted to short ABI above $25 under these conditions.
Cheers, Tuck |
